William Blair analyst Margaret Kaczor has maintained their bullish stance on GKOS stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Margaret Kaczor’s rating is based on Glaukos’s impressive financial performance and growth prospects, particularly in the fourth quarter where they reported revenue of $105 million, surpassing both their own and market expectations. This milestone, being the first time the company exceeded $100 million in quarterly revenue, was largely driven by significant growth in their glaucoma segment, especially within the United States. The iDose treatment has seen increased adoption among surgeons, contributing to a robust expansion in usage.
Despite certain challenges such as changes in local coverage determinations and the end of the Alcon/Hydrus royalty, Margaret Kaczor believes that the company’s 2025 guidance remains conservative. The potential for growth is supported by the successful integration of the iDose product, which is expected to continue providing substantial revenue contributions. Additionally, the company anticipates progress in reimbursement strategies, which could further enhance their financial performance. With these factors in mind, Glaukos presents a promising growth opportunity going forward.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $155.00 price target.
Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GKOS in relation to earlier this year.